Web Results

en.wikipedia.org/wiki/Quinupristin/dalfopristin

Quinupristin/dalfopristin (trade name Synercid) is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant ...

en.wikipedia.org/wiki/Quinupristin

Quinupristin is an antibiotic, often used in combination with dalfopristin under the trade name Synercid. It is active against Gram-positive bacteria, atypical but not ...

www.accessdata.fda.gov/drugsatfda_docs/label/2008/050748s008,050747s008lbl.pdf

(quinupristin and dalfopristin for injection). One of Synercid's approved indications is for the treatment of patients with serious or life-threatening infections.

www.aafp.org/afp/2001/1201/p1863.html

Dec 1, 2001 ... Quinupristin-dalfopristin is a streptogramin. This class of antibiotics is an important addition to the options available for the treatment of severe ...

reference.medscape.com/drug/synercid-quinupristin-dalfopristin-342575

Medscape - Infection dosing for Synercid (quinupristin/dalfopristin), frequency- based adverse effects, comprehensive interactions, contraindications, pregnancy  ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC1312217

Quinupristin/dalfopristin (Synercid, Rhone-Poulenc Rorer, Collegeville, Penn) is a member of the macrolide-lincosamide-streptogramin class of antibiotics.

www.ncbi.nlm.nih.gov/pubmed/11219478

Quinupristin/dalfopristin is a new combination streptogramin product with a selective spectrum of antibacterial activity, mainly against gram-positive aerobic ...

www.drugs.com/cdi/quinupristin-dalfopristin.html

Easy to read patient leaflet for quinupristin/dalfopristin. Includes indications, proper use, special instructions, precautions, and possible side effects.

www.drugbank.ca/drugs/DB01369

Jul 6, 2007 ... Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus ...

www.antimicrobe.org/drugpopup/Quinupristin-dalfopristin.htm

Venous irritation due to quinupristin/dalfopristin is common. In comparative trials approximately 40% of patients experienced infusion site adverse reactions ...

Related Search